BeOne Medicines Ltd ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $6.1B+60.9% YoYTTM through 30 Jun 2026
Net Income $655.7MTTM through 30 Jun 2026
Free Cash Flow $1.3BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 88.9% |
| EBITDA Margin | 17.6% |
| Operating Margin | 15.1% |
| Net Margin | 10.7% |
Returns
12.7%ROE
7.1%ROA
57.1%ROIC
Balance Sheet Health
Debt / Equity0.21x
Current Ratio3.40x
Net Debt-$4Bnet cash position
Cash & Equivalents$5.1B
Quality Metrics
Altman Z-Score6.71
Piotroski F-Score8 / 9
FCF Margin21.7%
Rule of 4031.9
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $5.3B
Diluted EPS$0.43TTMFY2025: $0.19
Dividend
No dividend
Capital Allocation
R&D Spend$2.3B
Capex Intensity2.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| China | $1.7B | ||
| Ex-China | $3.7B |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.